Combined High-Dose Caspofungin and Liposomal Amphotericin B for Treatment of Azole-Resistant Cerebral Aspergillosis

Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0047421. doi: 10.1128/AAC.00474-21. Epub 2021 Jul 12.

Authors

A Pouvaret¹, A Duréault¹, D Garcia-Hermoso², A Serris¹, J F Cohen¹, R Guery¹, F Lanternier^{1

2}, O Lortholary^{1

2}

Affiliations

¹ Paris University, Necker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, AP-HP, IHU Imagine, Paris, France.
² Institut Pasteurgrid.428999.7, CNRS, National Reference Center for Invasive Mycoses and Antifungals (NRCMA), Molecular Mycology Unit, UMR2000, Paris, France.

No abstract available

Keywords: azole resistance; central nervous system; invasive aspergillosis.

Publication types

Case Reports
Letter

MeSH terms

Aged
Amphotericin B* / therapeutic use
Antifungal Agents* / therapeutic use
Aspergillosis* / drug therapy
Azoles*
Caspofungin / therapeutic use*
Drug Resistance, Fungal
Echinocandins
Female
Humans
Lipopeptides

Substances

Antifungal Agents
Azoles
Echinocandins
Lipopeptides
liposomal amphotericin B
Amphotericin B
Caspofungin